Vascular Endothelial Growth Factor (VEGF) Imaging Before and During Everolimus Treatment for Renal Cell Carcinoma (Everolimage)
|ClinicalTrials.gov Identifier: NCT01028638|
Recruitment Status : Completed
First Posted : December 9, 2009
Last Update Posted : January 28, 2015
Everolimus indirectly inhibits angiogenesis by reducing VEGF production. VEGF can be non-invasively visualized and quantified with serial 89Zr-bevacizumab PET imaging in patients.
The investigators hypothesize that a decline in VEGF early during everolimus treatment in patients with metastatic renal cell carcinoma predicts treatment efficacy.
89Zr-bevacizumab PET scans will be performed at baseline, after 2 and 6 weeks of everolimus treatment in 14 adult patients with metastatic renal cell carcinoma.
|Condition or disease||Intervention/treatment|
|Metastatic Renal Cell Carcinoma||Other: 89Zr-bevacizumab PET scan|
Show Detailed Description
|Study Type :||Observational|
|Actual Enrollment :||13 participants|
|Official Title:||89Zr-bevacizumab PET Imaging in Patients With Renal Cell Carcinoma Treated With Everolimus; a Pilot Study|
|Study Start Date :||December 2009|
|Actual Primary Completion Date :||January 2015|
|Actual Study Completion Date :||January 2015|
Renal Cancer patients treated with everolimus
Other: 89Zr-bevacizumab PET scan
A tracer dose of 89Zr-bevacizumab (37 MBq, 5 mg protein dose) is given intravenously at day -3, day 11 and day 39.
PET scans are made on day 1, day 15 and day 43.
Other Name: VEGF imaging
- Change in 89Zr-bevacizumab uptake in tumor lesions between the baseline scan and the scan during treatment [ Time Frame: Baseline, 2 weeks and 6 weeks ]
- Progressive disease according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria, after 3 months of treatment [ Time Frame: 3 months ]
Biospecimen Retention: Samples With DNA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01028638
|University Medical Centre Groningen|
|Groningen, Netherlands, 9700 RB|
|Principal Investigator:||Sjoukje Oosting, MD||University Medical Center Groningen|